Discover how Par 5 Business is driving tangible outcomes and helping shape the future of cancer in Australia.
Pancreatic
This pioneering research is developing an implantable device that delivers chemotherapy directly into pancreatic tumours. By targeting treatment where it is needed most, the technology aims to improve the effectiveness of chemotherapy, reduce side effects and increase the number of patients eligible for life-saving surgery.
READ MORE
Stomach
This ground-breaking research is exploring whether approved migraine drugs can be used to slow gastric cancer growth. By repurposing existing medications, the project has the potential to fast-track new treatment options and improve outcomes for people affected by upper gastrointestinal cancers.
READ MORE
Eliza Wilmot Scholarship
Scholarships
2026 – Dr Lisa Mielke and Dr Pavitha Parathan at the Olivia Newton-John Cancer Research Institute
The Eliza Wilmot Scholarship was established by Par 5 in 2026 to honour the life and legacy of Eliza Wilmot, a remarkable young mother and advocate who was diagnosed with Stage IV stomach cancer at just 37 years old. Eliza's courage, determination and commitment to raising awareness inspired many within the Pancare community. Following her passing, the scholarship was created to ensure her legacy continues to drive meaningful change for families affected by upper gastrointestinal (GI) cancers.
The scholarship supports promising research projects that have the potential to improve outcomes for people diagnosed with upper GI cancers. By investing in innovative ideas and the researchers behind them, the program helps accelerate progress towards better treatments, earlier diagnosis and improved survival.
In its inaugural year, the Eliza Wilmot Scholarship was awarded to researchers Dr Lisa Mielke and Dr Pavitha Parathan at the Olivia Newton-John Cancer Research Institute. Their research is exploring a promising new treatment pathway that could enable approved migraine medications to be repurposed as a treatment for stomach cancer and potentially other upper GI cancers.